Alpha-1 Antitrypsin Deficiency Treatment Market Research Report Information By Drugs (Alpha-1 Proteinase Inhibitor, Bronchodilators, Steroids), Route of Administration (Oral, Intravenous, Inhalation) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) - Forecast to 2030

Alpha-1 Antitrypsin Deficiency Treatment Market Overview

Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 3.4 Billion by 2030 at a CAGR of 10.9%. Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency. Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the market growth of the alpha-1 antitrypsin deficiency treatment.

Strategic mergers & acquisitions are also projected to boost alpha-1 antitrypsin deficiency treatment market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.

High unmet medical needs in developing economies are directly providing lucrative opportunities for the alpha-1 antitrypsin deficiency treatment market growth.

Market Influencers

The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.

Market Drivers

• 
  Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive market growth of the alpha-1 antitrypsin deficiency treatment.


• Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs


• Rising awareness regarding alpha-1 antitrypsin deficiency


• High unmet medical needs in developing economies


• Increasing R&D expenditure by key players to develop innovative treatment options for AATD

Market Restraints

• Stringent government regulatory policies


• High cost of drugs

Alpha-1 Antitrypsin Deficiency Treatment Market Segmentation Insights

Alpha-1 Antitrypsin Deficiency Treatment Drugs Insights

• Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the alpha-1 antitrypsin deficiency treatment market growth.


• Bronchodilators: Used for prevention from upper respiratory tract infections.


• Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.


• Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.

Alpha-1 Antitrypsin Deficiency Treatment Route of Administration Insights

• Oral: This route of administration is expected to hold the largest alpha-1 antitrypsin deficiency treatment market share due to its high usage.


• Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.


• Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.


• Others: Consists of subcutaneous and intramuscular routes of administration.

Alpha-1 Antitrypsin Deficiency Treatment Distribution Channel Insights

• Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.


• Retail Pharmacy: They provide prescriptions that are intended to be used at home.


• Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.

Alpha-1 Antitrypsin Deficiency Treatment Regional Insights

• Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the market growth of alpha-1 antitrypsin deficiency treatment. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the market growth of the alpha-1 antitrypsin deficiency treatment in the region.


• Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the alpha-1 antitrypsin deficiency treatment market growth.


• Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world’s largest population and fast-developing healthcare industry which is anticipated to drive the market growth.


• Middle East & Africa: The market growth of alpha-1 antitrypsin deficiency treatment is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.

Key Players

• Kamada Pharmaceuticals (Israel): Offers Glassia, an alpha-1 antitrypsin deficiency treatment drug. It also has inhalation AATD drug in Phase 2 clinical trials in the US and phase 3 clinical trials in Europe.


• CSL Behring LLC (US): Leading provider of plasma-derived and recombinant therapeutic products for rare diseases such as AATD. Hosted the symposium about AATD treatment in Paris.


• Grifols, S.A. (Spain): Offers the Grifols Prolastin -C Liquid (alpha-1 proteinase inhibitor) for the treatment of AATD since 2017.


• Takeda Pharmaceutical Company Limited (Japan): Manufactures drugs for emphysema which is a main form of AATD.


• GlaxoSmithKline plc (UK): The company offers bronchodilators for the treatment of AATD.


• Boehringer Ingelheim GmbH (Germany): Manufacturer and distributor for bronchodilators.


• AstraZeneca (UK): Offers bronchodilators such as the Bevespi Aerosphere inhalation aerosol for treatment of COPD associated with AATD.


• Vectura Group plc (UK): Offers Ultibro Breezhaler dual bronchodilator.


• Pfizer Inc. (US): Offers the Spiriva Handihaler bronchodilator for the treatment of COPD associated with AATD.


• Mylan Inc. (US): Received FDA approval in November 2018 for YUPELRI, a long-acting muscarinic antagonist nebulized bronchodilator.